1. Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM.Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 2014; 6: 149-170.
2.
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C,Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D, POLA Network. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 2019; 21: 1519-1528.
3.
Bartels S, van Luttikhuizen JL, Christgen M, Mägel L, Luft A, Hänzelmann S, Lehmann U, Schlegelberger B, Leo F, Steinemann D, Kreipe H. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer. J Pathol 2018; 245: 373-383.
4.
Bhattacharya R, Fan F, Wang R, Ye X, Xia L, Boulbes D, Ellis LM.Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br J Cancer 2017; 117: 848-855.
5.
Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell 2018; 173: 530.
6.
Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP. Glioblastoma in England: 2007-2011. Eur J Cancer 2015; 51: 533-542.
7.
Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
8.
Chen L, Zeng D, Xu N, Li C, Zhang W, Zhu X, Gao Y, Chen PR, Lin J. Blood-brain barrier- and blood-brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases. ACS Appl Mater Interfaces 2019; 11: 41889-41897.
9.
Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics 2017; 14: 284-297.
10.
Chiappelli F, Phil AB, Arora R, Phi L, Giroux A, Uyeda M, Kung J, Ramchandani M. Reliability of quality assessments in research synthesis: Securing the highest quality bioinformation for HIT. Bioinformation 2012; 8: 691-694.
11.
Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 2016; 21: 965.
12.
Grek CL, Sheng Z, Naus CC, Sin WC, Gourdie RG, Ghatnekar GG. Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol 2018; 41: 79-88.
13.
Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N, Achiha T,Umehara T, Arita H, Kagawa N, Kanemura Y, Shimosegawa E,Hashimoto N, Hatazawa J, Kishima H, Teshima T, Ogawa K. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg 2019; 131: 676-686.
14.
Jones PS, Yekula A, Lansbury E, Small JL, Ayinon C, Mordecai S,Hochberg FH, Tigges J, Delcuze B, Charest A, Ghiran I, Balaj L, Carter BS. Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma. EBioMedicine 2019; 48: 23-35.
15.
Kamarudin MNA, Parhar I. Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review. Oncotarget 2019; 10: 3952-3977.
16.
Lim S, Kaldis P. CDKs, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013; 140: 3079-3093.
17.
Lin AJ, Campian JL, Hui C, Rudra S, Rao YJ, Thotala D, Hallahan D, Huang J. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol 2018; 136: 403-411.
18.
Lu VM, O’Connor KP, Shah AH, Eichberg DG, Luther EM, Komotar RJ, Ivan ME. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neurooncol 2020; 148: 221-229.
19.
Mon-López D, Tejero-González CM. Validity and reliability of the TargetScan ISSF Pistol & Rifle application for measuring shooting performance. Scand J Med Sci Sports 2019; 29: 1707-1712.
20.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019; 29: 212-226.
21.
Pessôa IA, Amorim CK, Ferreira WAS, Sagica F, Brito JR, Othman M,Meyer B, Liehr T, de Oliveira EHC. Detection and correlation of single and concomitant TP53, PTEN, and CDKN2A alterations in gliomas. Int J Mol Sci 2019; 20: 2658.
22.
Qi X, Wan Y, Zhan Q, Yang S, Wang Y, Cai X. Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants. Mamm Genome 2016; 27: 1-7.
23.
Schafer KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-478.
24.
Schill R, Solbrig S, Wettig T, Spang R. Modelling cancer progression using Mutual Hazard Networks. Bioinformatics 2020; 36: 241-249.
25.
Serra S, Chetty R. p16. J Clin Pathol 2018; 71: 853-858.
26.
Sibin MK, Bhat DI, Narasingarao KV, Lavanya C, Chetan GK. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. Tumour Biol 2015; 36: 7607-7614.
27.
Srivastava C, Irshad K, Dikshit B, Chattopadhyay P, Sarkar C, Gupta DK, Sinha S, Chosdol K. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma. Int J Cancer 2018; 142: 805-812.
28.
Sun X, Ma X, Wang J, Zhao Y, Wang Y, Bihl JC, Chen Y, Jiang C. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget 2017; 8: 36137-36148.
29.
Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, Tu Y, Zhang Y. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol 2012; 29: 3484-3490.
30.
Xiong L, Wang F, Qi Xie X. Advanced treatment in high-grade gliomas. J BUON 2019; 24: 424-430.
31.
Yang BY, Song JW, Sun HZ, Xing JC, Yang ZH, Wei CY, Xu TY, Yu ZN, Zhang YN, Wang YF, Chang H, Xu ZP, Hou M, Ji MJ, Zhang YS.PSMB8 regulates glioma cell migration, proliferation, and apoptosis through modulating ERK1/2 and PI3K/AKT signaling pathways. Biomed Pharmacother 2018; 100: 205-212.
32.
Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598-602.
33.
Yang Y, Duan W, Liang Z, Yi W, Yan J, Wang N, Li Y, Chen W, Yu S, Jin Z, Yi D. Curcumin attenuates endothelial cell oxidative stress injury through Notch signaling inhibition. Cell Signal 2013; 25: 615-629.
34.
Yi R, Feng J, Yang S, Huang X, Liao Y, Hu Z, Luo M. miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling. J Mol Histol 2018; 49: 209-218.
35.
Yu L, Xu J, Liu J, Zhang H, Sun C, Wang Q, Shi C, Zhou X, Hua D, Luo W, Bian X, Yu S. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients. Neuro Oncol 2019; 21: 742-754.
36.
Zhang M, Liu S, Guan E, Liu H, Dong X, Hao Y, Zhang X, Zhao P, Liu X, Pan S, Wang Y, Wang X, Liu Y. Hyperbaric oxygen therapy can ameliorate the EMT phenomenon in keloid tissue. Medicine (Baltimore) 2018; 97: e11529.
37.
Zhang Q, Cao YF, Ran RX, Li RS, Wu X, Dong PP, Zhang YY, Hu CM, Wang WM. Strong specific inhibition of UDP-glucuronosyltransferase 2B7 by atractylenolide I and III. Phytother Res 2016; 30: 25-30.
